Furthermore, we found that inhibition of both FGFR4 and EZH2 showed a synergistic effect on HCC treatment via repressing YAP signaling, which might provide a potential option for HCC patients in the future (Fig. 7). This evidence concerns the gene EZH2 and hepatocellular carcinoma.